Clinical trial
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney…
NCT00003656 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00003656 |
|---|---|
| Title | Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer |
| Official title | Phase II Trial of Atragen and Interferon Alfa-2b in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, tretinoin liposome |
| Enrollment | 26 |
| Start date | Jan 1, 1999 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 18, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: